Press Release

Kirkland Advises EQT on Sale of HTL-Strefa

Kirkland & Ellis is advising EQT Partners on its sale of leading medical device company HTL-Strefa (‘HTL’) to Investindustrial for an undisclosed consideration. Headquartered in Poland, HTL is a global market-leader in blood micro-sampling devices and provides products to over 80 countries. Following this transaction, which was announced on May 16, 2018, HTL will be combined with PIC, the healthcare business of Investindustrial portfolio company Artsana.

The Kirkland team, in London, was led by corporate partners Roger Johnson and Joel Arnell.

More information is available here.